(LNTH) Lantheus Holdings, Inc. Business Model Canvas Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(LNTH) Lantheus Holdings, Inc. Complete Analysis Pack
Lantheus Holdings: Business Model Canvas at a Glance
Unlock the full strategic blueprint behind Lantheus Holdings, Inc.’s business model. This concise Business Model Canvas shows how the company creates value in diagnostic imaging, serves key healthcare customers, and drives revenue through specialized products and partnerships. Download the full version for deeper, decision-ready insights.
Partnerships
GE Healthcare Limited
GE Healthcare Limited is a key imaging partner for Lantheus, helping move nuclear medicine and radiopharmaceutical products into more hospitals and clinics. The tie-up adds technical depth in diagnostic imaging and supports scale; Lantheus reported 2025 revenue of $1.3 billion, showing how important access and commercialization partners are.
Bayer AG
Bayer AG is a key oncology partner for Lantheus Holdings, Inc., helping advance and commercialize imaging tools for prostate cancer, a market with about 313,780 new U.S. cases projected in 2026. This tie-up supports Lantheus Holdings, Inc.'s PSMA imaging push and broadens access to advanced diagnostics.
NanoMab Technology Limited
NanoMab Technology Limited helps Lantheus Holdings, Inc. widen its external R&D base for targeted radiopharmaceuticals, supporting antibody- and ligand-based imaging programs. This matters as Lantheus has scaled to more than $1 billion in annual revenue in recent years, so partner-led discovery can add pipeline depth without loading all the fixed cost in-house.
Curium and ROTOP
Curium and ROTOP strengthen Lantheus Holdings, Inc.’s nuclear medicine supply chain by helping move isotope-linked products and radiopharmaceuticals into specialty diagnostic markets. Curium brings broad commercial reach, while ROTOP adds EU distribution depth, supporting access to high-value imaging channels where timing and isotope supply are critical.
- Supports isotope-linked product flow
- Expands radiopharmaceutical distribution
- Improves access to niche diagnostics
Bausch Health, CytoDyn, Regeneron, POINT Biopharma
Lantheus Holdings, Inc. ties its development work to 4 named partners here: Bausch Health, CytoDyn, Regeneron, and POINT Biopharma. The mix spans marketed products and investigational assets, giving Lantheus outside science, IP, and clinical expertise; POINT Biopharma also showed this model’s value, with Lantheus buying it for about $1.0 billion in 2024.
- 4 key partners
- Marketed and pipeline assets
- External science and IP access
- Clinical development support
Lantheus’ Partner Network Powers Growth Across Nuclear Medicine
Lantheus Holdings, Inc. relies on partners to scale imaging, supply, and pipeline work across nuclear medicine. GE Healthcare Limited, Bayer AG, NanoMab Technology Limited, Curium, ROTOP, Bausch Health, CytoDyn, Regeneron, and POINT Biopharma help extend reach, share R&D risk, and support commercial access as 2025 revenue reached $1.3 billion.
| Partner | Role |
|---|---|
| GE Healthcare Limited | Imaging access |
| Bayer AG | PSMA oncology |
| POINT Biopharma | Pipeline deal |
What is included in the product
Detailed Word Document
A concise Business Model Canvas overview of Lantheus Holdings, Inc., covering its diagnostic imaging products, customers, channels, and growth drivers.
Customizable Excel Spreadsheet
Helps quickly spot Lantheus Holdings’ key business pain points and opportunities in one editable, board-ready view.
Reference Sources
Provides a credible source trail for Lantheus Holdings, Inc. that supports faster due diligence and more confident decisions.
Activities
Radiopharmaceutical R&D
Lantheus Holdings, Inc. focuses its radiopharmaceutical R&D on 3 named pipeline assets: flurpiridaz F 18, 1095, and LMI 1195. The work targets cardiovascular disease, prostate cancer, and neuroblastoma, building on the Company’s core diagnostics and therapy platform.
Manufacturing and quality control
Lantheus Holdings, Inc. manufactures contrast agents, generators, and radiochemical products, so manufacturing and quality control sit at the center of its business model. The company needs tight GMP systems and release testing to keep isotope-based supply chains reliable, because any batch failure can delay patient imaging and treatment.
Clinical and regulatory development
Lantheus runs clinical trials and regulatory filings for imaging agents, software, and therapeutics, because approval work is what turns R&D into sales. In 2025, that focus supported a portfolio built around PYLARIFY and other pipeline assets, with each submission aimed at winning market access in the U.S. and abroad.
Commercialization and medical education
Lantheus Holdings, Inc. sells its nuclear medicine and cardiology products to hospitals, clinics, and radiopharmacies, and its field teams help train users so adoption sticks. In fiscal 2025, that commercial engine supported recurring demand across a portfolio that generated about $1.5 billion in revenue, with PYLARIFY remaining the main growth driver.
- Targets hospitals, clinics, radiopharmacies
- Field support drives clinical adoption
- Recurring demand depends on execution
AI and software development
Lantheus is building PYLARIFY AI to standardize PSMA PET/CT reads, which can make scan scoring more consistent and faster for clinicians. This pushes Lantheus beyond physical pharmaceuticals into digital diagnostics, supporting quantitative interpretation and smoother workflow across oncology imaging.
- Standardizes PSMA PET/CT analysis
- Extends revenue into software
- Improves read speed and consistency
Lantheus 2025: PYLARIFY Drives $1.5B as Pipeline Advances
Lantheus Holdings, Inc. key activities in fiscal 2025 centered on R&D, GMP manufacturing, and regulatory execution for radiopharmaceuticals, with 3 named pipeline assets: flurpiridaz F 18, 1095, and LMI 1195. Commercial work stayed focused on PYLARIFY and other nuclear medicine products, helping drive about $1.5 billion in revenue.
| Key activity | 2025 data |
|---|---|
| Pipeline focus | 3 assets |
| Revenue | About $1.5 billion |
| Growth driver | PYLARIFY |
Full Version Awaits
Business Model Canvas
This preview shows the actual Lantheus Holdings, Inc. Business Model Canvas you’ll receive after purchase. It is not a sample or mockup—what you see here is a direct view of the final document. Once purchased, you’ll unlock the same fully formatted file, ready to edit, present, and use.
Resources
Commercial product portfolio
Lantheus Holdings, Inc.’s commercial portfolio spans DEFINITY, TechneLite, PYLARIFY, AZEDRA, and RELISTOR, giving it both imaging diagnostics and therapeutics across cardiology, nuclear medicine, oncology, and GI care. PYLARIFY is the revenue anchor, with annual sales near $1B, while the broader mix supports a diversified revenue base.
Late-stage pipeline assets
Lantheus Holdings, Inc. has 5 late-stage assets across imaging and treatment: flurpiridaz F 18, 1095, LMI 1195, PYLARIFY AI, and leronlimab. Flurpiridaz F 18 is in Phase 3 for cardiac PET imaging, while PYLARIFY AI aims to sharpen PSMA scan reads, broadening growth beyond the core PYLARIFY franchise.
Radiopharmaceutical know-how
Lantheus Holdings, Inc. radiopharmaceutical know-how spans isotopes, generators, and nuclear medicine chemistry, a hard-to-copy capability at the core of its moat. In FY2024, PYLARIFY delivered over $1 billion in sales, showing how this expertise supports product development, manufacturing, and FDA execution.
Regulatory approvals and product rights
Lantheus Holdings, Inc. relies on FDA approvals and product rights for products like PYLARIFY, because approved indications and patents set the legal moat. That moat supports pricing power and helped drive FY2024 revenue to $1.53 billion, with PYLARIFY remaining the core commercial asset.
- Approved indications limit direct copycat entry
- Patent and license rights protect cash flows
- Regulatory status supports premium pricing
Partner network and brand
Lantheus Holdings, Inc. uses a broad partner network and trusted medical-imaging brand to keep clinician and buyer loyalty strong. Its North Billerica, Massachusetts headquarters anchors operations and support for a business that serves hospitals and imaging centers across the U.S. and abroad.
- Wide industry and customer network
- Trusted brand in medical imaging
- North Billerica HQ anchors operations
Lantheus’ Radiopharma Engine Powers $1.53B in FY2024 Revenue
Lantheus Holdings, Inc.’s key resources are its FDA-approved radiopharmaceutical brands, late-stage pipeline, and hard-to-copy isotope and nuclear medicine know-how. FY2024 revenue was $1.53 billion, with PYLARIFY topping $1 billion in sales.
| Key resource | FY2024 data |
|---|---|
| PYLARIFY | >$1.0B sales |
| Revenue | $1.53B |
| Late-stage assets | 5 programs |
Value Propositions
Accurate cardiac diagnosis
DEFINITY and related cardiology products help clinicians evaluate heart function in echocardiography and myocardial imaging, improving image clarity and diagnostic confidence in cardiovascular disease. Lantheus Holdings, Inc. reported 2025 revenue of about $1.5 billion, showing how central these workflows are to the business.
Prostate cancer imaging
PYLARIFY helps visualize PSMA-positive disease in lymph nodes, bone, and soft tissue, which makes recurrent or metastatic prostate cancer easier to detect. Lantheus reported PYLARIFY as a major driver of oncology imaging, with U.S. sales above $700 million in recent reported results and more than 1 million scans performed, showing strong clinical pull.
Broad nuclear medicine access
TechneLite, Cardiolite, Neurolite, Xenon-133, Thallium-201, and Gallium-67 give Lantheus Holdings, Inc. broad coverage in routine nuclear medicine, spanning cardiac, brain, lung, and tumor imaging. These isotopes support daily hospital and imaging-center workflows; for example, Xenon-133 has a 5.25-day half-life, while Thallium-201 is used for myocardial perfusion imaging.
Theranostic treatment options
AZEDRA and Lantheus Holdings, Inc. pipeline therapies extend the Company into treatment, not just imaging. That theranostic model links diagnosis and therapy in one radiopharmaceutical workflow, and the FDA-approved AZEDRA asset targets a niche oncology market with high clinical value.
- Diagnosis plus therapy in one path
- Higher-value clinical and commercial use
That mix can deepen physician adoption and support premium economics as radiopharmaceutical use grows.
Quantitative decision support
Automated Bone Scan Index and PYLARIFY AI add standardized reads to imaging, which can lift consistency and speed in oncology workflows. In Lantheus Holdings, Inc., PYLARIFY delivered $808.9 million in FY2024 net sales, showing how data-backed diagnostics can support faster, more repeatable care decisions.
- Standardizes imaging analysis
- Speeds interpretation
- Supports oncology decisions
Lantheus Drives Growth with DEFINITY and PYLARIFY
Lantheus Holdings, Inc. sells high-value imaging products that improve diagnosis in cardiology and oncology, with DEFINITY supporting clearer echocardiograms and PYLARIFY helping detect PSMA-positive prostate cancer. In fiscal 2025, Company revenue was about $1.5 billion, and PYLARIFY remained a major growth engine.
| Value proposition | Data |
|---|---|
| Cardiology imaging | DEFINITY |
| Oncology imaging | PYLARIFY FY2025 sales above $700M |
Customer Relationships
Enterprise account support
Lantheus Holdings, Inc. supports hospitals, IDNs, and large medical practices with direct account management, so enterprise customers get steady supply planning and technical coordination around recurring demand. This model fits high-volume radiopharmaceutical use, where service uptime and order reliability matter more than one-off sales.
Radiopharmacy and distributor service
Lantheus Holdings, Inc. works closely with radiopharmacies and distributors to keep time-sensitive nuclear medicine products moving on schedule; in 2024, Company reported revenue of about $1.40 billion, so supply reliability matters. These intermediaries need predictable fill rates, cold-chain logistics, and fast issue resolution because even short delays can disrupt patient dosing.
Clinical education and field support
Clinical education and field support matter because Lantheus Holdings, Inc. sells imaging agents that depend on correct protocols and interpretation. In FY2025, the company had roughly $1.5 billion in revenue, and its medical affairs and field teams help clinicians use products with more confidence, which supports repeat use and broader adoption.
That hands-on training is especially important in imaging centers, where small protocol errors can affect scan quality. Better education lifts utilization and helps turn complex products into routine practice.
Long-term supply relationships
Lantheus Holdings, Inc. builds long-term supply ties because its imaging agents are used again and again in routine diagnostics, so hospitals and imaging centers reorder on a steady cycle. In FY2024, the business was still driven by recurring radiopharmaceutical demand, where reliability, exact delivery timing, and FDA/GMP compliance matter as much as image quality.
- Repeat-use diagnostics support recurring orders.
- Compliance reduces supply and care risk.
- Reliability shapes customer retention.
Partner-led collaboration management
Partner-led collaboration management keeps Lantheus Holdings, Inc. external innovation on track through shared scientific goals, clear governance, and milestone reviews. It also spreads development risk, which matters as the Company scales partnered radiopharma programs and manages a 2025 R&D spend of about $200 million.
- Align science before each milestone
- Use governance to manage risk
- Push pipeline with partners
Lantheus Builds Customer Loyalty With Support, Training, and Supply
Lantheus Holdings, Inc. keeps customer ties tight through direct account support, clinical training, and dependable supply for hospitals, IDNs, imaging centers, radiopharmacies, and distributors. FY2025 revenue was about $1.5 billion, and roughly $200 million in R&D helped fund the medical support and partner coordination these customers rely on.
| Customer tie | FY2025 data |
|---|---|
| Revenue | ~$1.5B |
| R&D spend | ~$200M |
Channels
Radiopharmacies
Radiopharmacies are a critical delivery channel for Lantheus Holdings, Inc. because they prepare and ship short-lived nuclear medicine doses to care sites, keeping imaging agents available when patients need them. In 2024, Lantheus generated about $1.3 billion in revenue, so even small delays in this channel can hit scan access and sales fast.
Distributors
Distributors help Lantheus Holdings, Inc. reach fragmented healthcare markets and move diagnostic products into hospitals, clinics, and specialty practices. This channel supports wider coverage and leaner logistics, which matters as Lantheus served a broad U.S. provider base across radiopharmaceutical and imaging workflows in its latest reporting period.
Hospitals and IDNs
Hospitals and IDNs are a key channel for Lantheus Holdings, Inc., because core products like PYLARIFY and DEFINITY are bought through centralized procurement and used at scale. In FY2024, Lantheus reported about $1.3 billion in revenue, showing how high-volume institutional demand can drive the business.
Specialty clinics and practices
Cardiology, oncology, and nuclear medicine practices use Lantheus Holdings, Inc. products in daily outpatient imaging and diagnostics, so they need fast ordering and reliable delivery. In 2025, Lantheus reported about $1.4 billion in revenue, showing how much this channel matters to recurring care use.
- Supports daily diagnostic workflows
- Needs simple ordering and steady supply
- Drives outpatient imaging demand
Field sales and medical affairs
Field sales and medical affairs help Lantheus Holdings, Inc. turn clinical data into adoption: reps and field medical teams explain value, fit in workflow, and product updates at the point of care. This matters across a company whose main growth engine is PYLARIFY, with 2024 net sales of $1.40 billion, because face-to-face education helps keep usage steady and relationships strong.
- Direct education supports adoption
- Explains clinical value and workflow fit
- Helps retain users over time
Lantheus’ Channels Power Scan Access and Revenue Growth
Channels for Lantheus Holdings, Inc. are radiopharmacies, distributors, hospitals, IDNs, and specialty practices, with field sales and medical affairs supporting adoption at the point of care. In FY2025, Company Name reported about $1.4 billion in revenue, so these channels directly shape scan access, product uptake, and repeat use.
| Channel | Role | FY2025 data |
|---|---|---|
| Radiopharmacies | Prepare and ship doses | Supports $1.4 billion revenue |
Customer Segments
Radiopharmacies
Radiopharmacies are key nuclear medicine buyers for Lantheus Holdings, Inc., because they need steady access to generators and radiochemical products to fill hospital and clinic orders. In fiscal 2024, Lantheus reported $1.53 billion in net sales, and this segment’s demand follows procedure volumes, so supply reliability and fast delivery matter most.
Hospitals
Hospitals are a core Lantheus Holdings, Inc. customer because they drive high-volume inpatient and outpatient imaging across cardiology, oncology, neurology, and pulmonary care. In 2024, Lantheus reported about $1.5 billion in revenue, and hospitals value its products for reliable supply, FDA compliance, and clinical support that keeps scans running when imaging demand is high.
Integrated delivery networks
Integrated delivery networks buy for many sites at once, so they want standard products and one vendor across hospitals, outpatient centers, and physician groups. Lantheus can fit that need with a broad imaging portfolio, which helps it win larger, systemwide contracts and reduce switching risk.
Clinics and group medical practices
Clinics and group medical practices use Lantheus Holdings, Inc. imaging agents and diagnostics in outpatient care, where fast scheduling and steady delivery matter. They support recurring use beyond large hospitals, and outpatient settings drive most diagnostic imaging volume in the U.S., so supply reliability directly affects throughput and revenue.
- Outpatient imaging needs fast workflows.
- Predictable supply reduces scan delays.
- Group practices drive repeat utilization.
Specialty oncology and cardiology centers
Specialty oncology and cardiology centers are core users of Lantheus Holdings, Inc.'s PYLARIFY and DEFINITY, where high diagnostic precision and on-site clinical support matter most. In 2025, PYLARIFY remained the company’s largest growth driver, with Lantheus reporting FY2025 revenue above $1 billion, and these centers fit advanced imaging because they manage complex cancer and cardiac cases.
- High-precision imaging demand
- Direct use of PYLARIFY, DEFINITY
- Need specialist support
Lantheus Revenue Grows on Imaging Demand and Supply Reliability
Lantheus Holdings, Inc. sells mainly to hospitals, radiopharmacies, outpatient imaging centers, IDNs, and specialty oncology and cardiology clinics. These buyers need reliable supply of PYLARIFY, DEFINITY, and radiopharmaceuticals, and FY2025 revenue topped $1 billion, showing demand is tied to scan volume and systemwide contracts.
| Customer segment | Need |
|---|---|
| Hospitals/IDNs | High-volume, compliant imaging |
| Radiopharmacies | Steady generator supply |
| Specialty clinics | Precision oncology/cardiology |
Cost Structure
Research and development
In fiscal 2025, Lantheus Holdings, Inc. kept research and development as a core cost, funding pipeline discovery, preclinical work, and clinical trials for new imaging agents, therapeutics, and software. That spend is the base for future growth, because each new program can expand the product mix and support long-term revenue.
Manufacturing and supply chain
Lantheus’ manufacturing and supply chain is cost heavy because radiopharmaceuticals and contrast agents need specialized cGMP facilities, isotope sourcing, and same-day delivery. Quality control is a big share of spend, since short half-life isotopes and sterile release testing leave little room for delay.
Sales, marketing, and medical affairs
Lantheus keeps commercial teams in the field to drive adoption of its B2B radiopharma products, and that spend rises as its portfolio and customer base grow. In 2025, sales, marketing, and medical affairs stayed a core opex line because the company must fund education, account management, and clinical support to move products through hospital and imaging channels.
Regulatory and compliance
In FY2025, Lantheus held recurring costs for FDA filings, safety reporting, and GMP quality systems; these are fixed costs that stay in place from development through commercialization. As its radiopharmaceutical portfolio grows, each new label, site, or inspection adds more compliance spend and internal headcount.
- FDA support never stops.
- Safety reporting is ongoing.
- Quality systems drive fixed costs.
Partner and licensing commitments
Lantheus Holdings, Inc. uses partner and licensing deals to speed pipeline work, but those contracts can trigger milestone payments, royalties, and shared development costs. The mix of external ties and internal spend means this line item moves with program progress and commercialization plans.
- Milestones hit when targets are reached
- Royalties rise with product sales
- Shared R&D lowers upfront risk
Lantheus FY2025: R&D and Radiopharma Manufacturing Drive Costs
In FY2025, Lantheus Holdings, Inc. cost structure was driven by R&D, specialized radiopharma manufacturing, and commercial support. The biggest fixed loads were cGMP production, isotope sourcing, quality control, FDA compliance, and field sales.
| Cost driver | FY2025 note |
|---|---|
| R&D | Core pipeline spend |
| Manufacturing | cGMP and isotope-heavy |
Revenue Streams
Diagnostic product sales
Diagnostic product sales are Lantheus Holdings, Inc.'s core revenue base: DEFINITY, TechneLite, PYLARIFY, Cardiolite, Neurolite, and other agents are sold through hospitals and clinics, so revenue rises with imaging and cardiology procedure volume. In FY2024, Lantheus generated about $1.54B in revenue, with PYLARIFY and DEFINITY doing most of the heavy lifting.
Therapeutic product sales
AZEDRA and RELISTOR add pharmaceutical revenue to Company Name, pushing it beyond diagnostics into treatment. In fiscal 2025, therapeutic sales helped broaden higher-value care exposure, alongside Company Name’s $1.3 billion-plus revenue base.
Generator and isotope sales
In FY2025, generator and isotope sales stayed a recurring cash source, led by TechneLite and related radiochemical products that nuclear medicine labs must replenish on schedule. Because demand is tied to ongoing clinical scans and short product lives, this stream is repeat-buy driven rather than one-off.
Collaboration, licensing, and milestones
Lantheus Holdings, Inc. uses collaboration, licensing, and milestone deals to bring in upfront cash, milestone payments, and royalties, while letting partners help fund and scale innovation beyond direct sales. This is a low-capex way to monetize R&D and cut development risk.
- Upfront cash
- Milestones on progress
- Royalties on sales
- Shares R&D risk
That mix helps diversify revenue and reduces dependence on one product launch cycle.
Software and digital diagnostics
PYLARIFY AI and automated imaging tools can add software fees on top of Lantheus Holdings, Inc.’s core diagnostic sales, with FY2025 company revenue already above $1 billion, so even small digital attach rates can matter. These tools also support recurring income through subscriptions, upgrades, and workflow software, while improving margins versus hardware-heavy products.
- Software adds recurring revenue.
- Digital tools lift diagnostic margins.
- PYLARIFY AI expands commercial reach.
Lantheus Revenue: Diagnostics Lead, Therapeutics and Partner Cash Add Growth
Lantheus Holdings, Inc. earns most revenue from diagnostic imaging agents, led by PYLARIFY and DEFINITY, with recurring demand tied to scan volume and repeat hospital use. FY2025 also added therapeutic sales, isotope replenishment, and partner cash from milestones, royalties, and licensing.
| Stream | FY2025 role |
|---|---|
| Diagnostics | Core sales |
| Therapeutics | Growth add-on |
| Partners | Milestones, royalties |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.